The NurOwn® Production Process

MSC-NTF cells are produced from autologous, bone marrow-derived MSCs that have been expanded and differentiated ex vivo. Bone marrow is aspirated from the patient under local anesthesia in the hospital, a routine and safe procedure that takes about 20 minutes and is performed routinely. The bone marrow aspirate is sent to the manufacturing facility, where the MSCs are separated from the other cells present, isolated and grown for approximately 2-3 weeks. At this point, the MSCs could be made directly into MSC-NTF cells, or frozen and stored for future doses.

The process of converting MSCs into MSC-NTF cells takes about six days. The cells are grown under our patented conditions, and are induced to secrete much higher levels of neurotrophic factors. At the end of this process they are harvested, placed into syringes and are ready to be delivered to the patient for administration. We are very proud that our production process uses no animal-derived products such as fetal calf serum, nor do we use antibiotics during production.

We have a number of important manufacturing initiatives underway in order to improve the efficiency, increase the scale, and decrease the cost of the manufacturing process. We also have an exciting collaboration


with Octane, in which we are developing a bioreactor that could potentially be used for the eventual commercial production of NurOwn®. We are working with Octane’s Cocoon bioreactor and developing a customized cartridge that will house and grow MSC-NTF cells.